Skip to main content

ADVERTISEMENT

Adrian F. Low, MD, MBBS

08/01/2008
Primary percutaneous transluminal coronary angioplasty (PTCA) has been consistently demonstrated to be superior to thrombolytic therapy and is currently the recommended therapy for myocardial infarction (MI).1 However, no-reflow phenomenon...
Primary percutaneous transluminal coronary angioplasty (PTCA) has been consistently demonstrated to be superior to thrombolytic therapy and is currently the recommended therapy for myocardial infarction (MI).1 However, no-reflow phenomenon...
Primary percutaneous...
08/01/2008
Journal of Invasive Cardiology
08/01/2008
CYPHER™ (sirolimus-eluting stent, Cordis, Johnson and Johnson, Miami, Florida) and TAXUS® (polymer-based paclitaxel-eluting stent, Boston Scientific Corporation, Natick, Massachusetts) stents are the two drug-eluting stents (DES) currently...
CYPHER™ (sirolimus-eluting stent, Cordis, Johnson and Johnson, Miami, Florida) and TAXUS® (polymer-based paclitaxel-eluting stent, Boston Scientific Corporation, Natick, Massachusetts) stents are the two drug-eluting stents (DES) currently...
CYPHER™ (sirolimus-eluting...
08/01/2008
Journal of Invasive Cardiology
Clinical Images
08/01/2008
Case Presentation. A 59-year-old male was admitted for accelerated angina. Serial ECGs and cardiac enzymes ruled out a myocardial infarction. He had undergone coronary artery bypass grafting 4 years before, as well as coronary stenting of an...
Case Presentation. A 59-year-old male was admitted for accelerated angina. Serial ECGs and cardiac enzymes ruled out a myocardial infarction. He had undergone coronary artery bypass grafting 4 years before, as well as coronary stenting of an...
Case Presentation. A 59-year-old...
08/01/2008
Journal of Invasive Cardiology
Original Contribution
08/01/2008
Drug-eluting stents (DES) have emerged as a novel technology in coronary revascularization. Ample evidence has shown that polymer-based DES effectively reduce in-stent restenosis and repeat revascularization after percutaneous coronary...
Drug-eluting stents (DES) have emerged as a novel technology in coronary revascularization. Ample evidence has shown that polymer-based DES effectively reduce in-stent restenosis and repeat revascularization after percutaneous coronary...
Drug-eluting stents (DES) have...
08/01/2008
Journal of Invasive Cardiology
04/15/2018
An evaluation of the 1-year clinical outcomes of patients treated with 2.0 mm drug-coated balloon vs 2.0 mm drug-eluting stent implantation in small-caliber vessel de novo coronary artery disease.
An evaluation of the 1-year clinical outcomes of patients treated with 2.0 mm drug-coated balloon vs 2.0 mm drug-eluting stent implantation in small-caliber vessel de novo coronary artery disease.
An evaluation of the 1-year...
04/15/2018
Journal of Invasive Cardiology